BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

More documents

Recommendations

Info

Table 4. TPT penetration after MDBT in mice bearing Rh30 RMS xenograft Parameters AUCt (ng•hr/L) AUCp (ng•hr/L) AUCt/AUCp Groups Mean SD CV% Mean SD CV% Mean SD CV% mT 428 77.1 18.0 165 28.4 17.2 2.68 0.859 32.0 1D mBT 519 161 31.0 169 29.0 17.1 3.06 0.787 25.7 3D mBT 370 180 48.7 154 52.9 34.3 2.40 0.673 28.0 7D mBT 516 144 27.8 168 51.0 30.3 3.17 0.787 24.8 SD refers to standard deviation and CV% refers to coefficient of variation (CV%= SD/Mean×%). 35
Figure 8. The effect of BEV on the intratumoral exposure, plasma exposure and intratumoral penetration of TPT after MDBT in mice bearing orthotopic Rh30 RMS xenograft The intratumoral and plasma exposure of TPT is shown in Panel A and B. The penetration of TPT is shown in Panel C. One way ANOVA analysis: p=0.297 for panel A; p=0.931 for panel B and p=0.307 for panel C 36
Page 1 and 2: BEVACIZUMAB EFFECT ON TOPOTECAN PHA
Page 3 and 4: ACKNOWLEDGEMENTS I would like to th
Page 5 and 6: overall effect of BEV on TPT pharma
Page 7 and 8: 2.3.1 The effect of BEV on the phar
Page 9 and 10: LIST OF FIGURES Figure 1. TPT effic
Page 11 and 12: SDBT Single dose of bevacizumab tre
Page 13 and 14: hypertension and the pathologic ext
Page 15 and 16: 1.1.3 Strategies to improve drug pe
Page 17 and 18: 1.2.2 Role of vascular endothelial
Page 19 and 20: enhanced the tumor response to conv
Page 21 and 22: non-favorable sites [109]. So devel
Page 23 and 24: low sensitivity. Additionally, it r
Page 25 and 26: tumor distribution of TMZ in V+ SC
Page 27 and 28: over-pruned microvessel [146, 147].
Page 29 and 30: 1.7 Summary Although the overall su
Page 31 and 32: CHAPTER 2. THE EFFECT OF BEVACIZUMA
Page 33 and 34: 2.2.4 Tumor model and treatment Ort
Page 35 and 36: Table 1. (SDBT) TPT penetration stu
Page 37 and 38: Figure 2. TPT penetration plus effi
Page 39 and 40: Figure 3. A pharmacokinetic model f
Page 41 and 42: 2.2.10 Statistical analyses For eac
Page 43 and 44: Figure 6. Representative plasma and
Page 45: Figure 7. The effect of BEV on the
Page 49 and 50: Table 6. Population PK parameters o
Page 51 and 52: variability for Kte decreased from
Page 53 and 54: Figure 11. The effect of different
Page 55 and 56: efflux transporters. TPT is a campt
Page 57 and 58: Furthermore, although the volume of
Page 59 and 60: 19. Sleeman, J., A. Schmid, and W.
Page 61 and 62: 56. ElBayoumi, T.A. and V.P. Torchi
Page 63 and 64: 91. Ma, J. and D.J. Waxman, Combina
Page 65 and 66: 125. Hao, M., et al., Pharmacokinet
Page 67 and 68: 154. Dickson, P.V., et al., Bevaciz
Page 69 and 70: 188. Tian, Q., et al., Topotecan is

BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

Create successful ePaper yourself

Delete template?

Save as template?